Display options
Cite
Yin Z, Gao M, Chu S, et al. Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells. Oncotarget. 2017;8(55):94210-94222doi: 10.18632/oncotarget.21618.
Yin, Z., Gao, M., Chu, S., Su, Y., Ye, C., Wang, Y., Pan, Z., Wang, Z., Zhang, H., Tong, H., & Zhu, J. (2017). Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells. Oncotarget, 8(55), 94210-94222. https://doi.org/10.18632/oncotarget.21618
Yin, Zhengna, et al. "Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells." Oncotarget vol. 8,55 (2017): 94210-94222. doi: https://doi.org/10.18632/oncotarget.21618
Yin Z, Gao M, Chu S, Su Y, Ye C, Wang Y, Pan Z, Wang Z, Zhang H, Tong H, Zhu J. Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells. Oncotarget. 2017 Oct 07;8(55):94210-94222. doi: 10.18632/oncotarget.21618. eCollection 2017 Nov 07. PMID: 29212222; PMCID: PMC5706868.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Oct 07;8(55):94210-94222. doi: 10.18632/oncotarget.21618. eCollection 2017 Nov 07.

Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells.

Oncotarget

Zhengna Yin, Mengyun Gao, Sasa Chu, Yiping Su, Chunping Ye, Yiquan Wang, Zhuanqin Pan, Zhuming Wang, Huilin Zhang, Hua Tong, Jin Zhu

Affiliations

  1. Department of Obstetrics and Gynecology, Nanjing Maternity and Child Health Care Hospital, Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing 210004, China.
  2. Department of Infectious Disease, Institute of Liver Disease, Nanjing Jingdu Hospital, Nanjing 210002, China.
  3. Department of Traditional Chinese Internal Medicine, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.
  4. Department of Nursing, Gaoyou People's Hospital, Yangzhou 225600, China.
  5. Department of Pathology, Chinese Ministry of Health-designated Key Laboratory of Antibody Technology, Nanjing Medical University, Nanjing 210029, China.
  6. Huadong Medical Institute of Biotechniques, Nanjing 210002, China.

PMID: 29212222 PMCID: PMC5706868 DOI: 10.18632/oncotarget.21618

Abstract

Receptor-tyrosine-kinase-like Orphan Receptor 1 (ROR1) is a tyrosine-protein kinase transmembrane receptor and ROR1 overexpression is associated with a poor prognosis in various cancers, including ovarian cancer. Targeting of ROR1 has been evaluated as a novel cancer therapy strategy. This study developed a novel chimeric anti-ROR1 Fab antibody (named ROR1-cFab) and then assessed the antitumor activity of this antibody in ovarian cancer cells, an

Keywords: ROR1; antitumor activity; binding affinity; chimeric antibody Fab; monoclonal antibody production

Conflict of interest statement

CONFLICTS OF INTEREST The authors declared that there is no conflicts of interest in this work.

References

  1. Cancer Cell. 2012 Mar 20;21(3):348-61 - PubMed
  2. J Immunol Methods. 2007 Jan 10;318(1-2):113-24 - PubMed
  3. Cancer Res. 2013 Jun 15;73(12):3649-60 - PubMed
  4. Cell. 2010 Jun 25;141(7):1117-34 - PubMed
  5. PLoS One. 2015 May 15;10(5):e0127092 - PubMed
  6. Cancer Med. 2017 Apr;6(4):768-777 - PubMed
  7. Cancer Cell. 2012 Nov 13;22(5):656-67 - PubMed
  8. Sci Rep. 2014 Jul 24;4:5811 - PubMed
  9. Clin Cancer Res. 2017 Jun 15;23 (12 ):3061-3071 - PubMed
  10. Annu Rev Biochem. 2000;69:373-98 - PubMed
  11. Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17266-71 - PubMed
  12. J Cell Sci. 2012 Apr 15;125(Pt 8):2017-29 - PubMed
  13. Int J Oncol. 2016 Jan;48(1):181-90 - PubMed
  14. Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3047-52 - PubMed
  15. PLoS One. 2010 Jul 29;5(7):e11859 - PubMed
  16. J Cell Sci. 2005 Jan 15;118(Pt 2):433-46 - PubMed
  17. Oncotarget. 2015 Nov 3;6(34):36003-18 - PubMed
  18. Nat Rev Cancer. 2003 Jul;3(7):502-16 - PubMed
  19. Crit Rev Oncol Hematol. 2011 Jul;79(1):17-23 - PubMed
  20. J Med Case Rep. 2016 Jul 25;10 :202 - PubMed
  21. Int J Biol Macromol. 2014 Jul;68:173-7 - PubMed
  22. Mol Oncol. 2016 May;10 (5):677-92 - PubMed
  23. Sci Rep. 2016 Nov 10;6:36447 - PubMed
  24. PLoS One. 2017 Apr 26;12 (4):e0174916 - PubMed
  25. J Hematol Oncol. 2017 May 19;10 (1):111 - PubMed
  26. Semin Cancer Biol. 2014 Dec;29:21-31 - PubMed
  27. J Exp Clin Cancer Res. 2015 Nov 14;34:139 - PubMed
  28. Virchows Arch. 2016 May;468(5):589-95 - PubMed
  29. Oncogenesis. 2016 May 30;5(5):e226 - PubMed
  30. Oncotarget. 2015 Nov 24;6(37):40310-26 - PubMed
  31. Endocr Relat Cancer. 2001 Sep;8(3):161-73 - PubMed
  32. Int J Womens Health. 2015 Feb 04;7:189-203 - PubMed
  33. PLoS One. 2012;7(3):e31127 - PubMed
  34. Leukemia. 2012 Jun;26(6):1348-55 - PubMed
  35. Front Endocrinol (Lausanne). 2014 Nov 12;5:192 - PubMed
  36. Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):793-8 - PubMed
  37. Hum Antibodies. 2017;25(1-2):57-63 - PubMed
  38. Front Immunol. 2016 Dec 26;7:649 - PubMed
  39. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 - PubMed
  40. Oncogene. 2000 Nov 20;19(49):5548-57 - PubMed
  41. Int J Cancer. 2008 Sep 1;123(5):1190-5 - PubMed
  42. Trends Cell Biol. 2008 Nov;18(11):536-44 - PubMed
  43. Sci Rep. 2016 Mar 24;6:23613 - PubMed
  44. Front Oncol. 2012 Apr 18;2:34 - PubMed

Publication Types